Surrozen, Inc.
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company focused on discovering and developing product candidates that selectively modulate the Wnt pathway, a critical mediator of tissue repair. Based in South San Francisco, California, the company is committed to transforming the treatment of serious ophthalmic… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Surrozen, Inc. does
In the company’s own words
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company focused on discovering and developing product candidates that selectively modulate the Wnt pathway, a critical mediator of tissue repair. Based in South San Francisco, California, the company is committed to transforming the treatment of serious ophthalmic diseases by harnessing the therapeutic potential of Wnt signaling in a tissue-selective manner.
The company's scientific foundation rests on groundbreaking work by its founders and scientific advisors, including Dr. Roel Nusse and Dr. Harold Varmus, who discovered the first Wnt gene in 1982. Building on these seminal discoveries, Surrozen has developed proprietary antibody engineering technologies, particularly its SWAP (Surrozen Wnt signal Activating Protein) platform, which enables the design of potent, selective, and manufacturable Wnt mimetics that overcome previous limitations in targeting the Wnt pathway.
Surrozen's lead product candidates are multi-specific, antibody-based therapeutics designed to activate Wnt signaling in diseased tissue. SZN-8141 combines Fzd4 agonism with VEGF antagonism for treating diabetic macular edema and neovascular age-related macular degeneration. SZN-8143 adds IL-6 antagonism to address diabetic macular edema, wet AMD, and uveitic macular edema. The company anticipates submitting an IND application for SZN-8141 in the second half of 2026.
Beyond its internal pipeline, Surrozen has established strategic partnerships to maximize the potential of its platform. In October 2022, the company executed a collaboration and license agreement with Boehringer Ingelheim to research, develop, and commercialize Fzd4 bi-specific antibodies, including SZN-413. This partnership has generated milestone payments, with Boehringer Ingelheim achieving a research milestone in March 2026 entitling Surrozen to a five million dollar payment.
The company also maintains a research collaboration with TCGFB, Inc., focusing on antibody therapeutics targeting transforming growth factor beta for idiopathic pulmonary fibrosis treatment. Additionally, Surrozen holds exclusive licenses to Wnt-related technology from Stanford University, with patent protection extending through 2035 and 2037.
Surrozen operates as a smaller reporting company and emerging growth company, with its research and development organization led by world-class scientists and supported by key thought leaders on its Scientific Advisory Board.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1824893
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Surrozen, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Surrozen, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Surrozen, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Surrozen, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Surrozen, Inc.'s last four quarterly filings that the numbers alone won't show?”